Professor Ridley’s research examines innovation and pricing, and led to his authoring a paper proposing the Priority Review Voucher program encouraging development of medications for neglected diseases that became law in 2007. He has consulted for life sciences companies including Amgen, Eli Lily, Genentech, GlaxoSmithKline, Novartis, and Pfizer.